The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Carl B

Carl Borrebaeck

Professor

Carl B

Viewpoints in Clinical Proteomics - when will proteomics deliver clinically useful information?

Author

  • Carl Borrebaeck

Summary, in English

Proteomics has not delivered biomarkers of clinical value, despite massive efforts. The technologies that are emerging today have, however, the power to reach deep into proteomes and to identify patterns associated with different diseases. The study design is then crucial and sample quality, bioinformatic approaches, pre-validation, using independent patient cohort, need to attract increased attention before proteomics will contribute to the needs of personalized medicine.

Department/s

  • Department of Immunotechnology
  • BioCARE: Biomarkers in Cancer Medicine improving Health Care, Education and Innovation

Publishing year

2012

Language

English

Pages

343-345

Publication/Series

Proteomics Clinical Applications

Volume

6

Issue

7-8

Document type

Journal article

Publisher

John Wiley & Sons Inc.

Topic

  • Cell and Molecular Biology

Keywords

  • over-fitting
  • biobanks
  • pre-validation
  • bioinformatics
  • Signatures

Status

Published

ISBN/ISSN/Other

  • ISSN: 1862-8354